Research programme: nanoparticle drug therapeutics - Nevakar

Drug Profile

Research programme: nanoparticle drug therapeutics - Nevakar

Alternative Names: Nanoparticle drugs - Nevakar; Nanoparticles - Nevakar

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nevakar
  • Class Anti-infectives; Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Infections

Most Recent Events

  • 29 Sep 2017 Nevakar in-licenses proprietary nanoparticle platform technology from Princeton University
  • 29 Sep 2017 Early research in Cancer in USA (unspecified route)
  • 29 Sep 2017 Early research in Infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top